ACLARIS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
ACLARIS THERAPEUTICS INC. - More news...
ACLARIS THERAPEUTICS INC. - More news...
- Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
- Thinking about buying stock in KE Holdings, Ford Motor, Vertiv Holdings, Cadrenal Therapeutics, or Aclaris Therapeutics?
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 01-19-2021
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 07-20-2020
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 06-17-2020
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 01-10-2020
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 10-29-2019
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 10-22-2019
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 10-07-2019
- DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS
- DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm
- LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
- GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS
- Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 08-13-2019
- ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ACRS
- IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
-
Aclaris Therapeutics, Inc. - ACRS Stock Chart Technical Analysis for 07-01-2019
- Investor Expectations to Drive Momentum within Casella Waste, Prologis, Flushing Financial, AMERISAFE, Aclaris Therapeutics, and NanoString Technologies — Discovering Underlying Factors of Influence
- Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International — Research Highlights Growth, Revenue, and Consolidated Results
- Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
- Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call
- Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors
- Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference
- Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
- Aclaris Therapeutics to Attend Upcoming Investor Conferences
- Aclaris Announces Pricing of Public Offering of Common Stock
